Hudson Bay Capital Management
ACRS icon

Hudson Bay Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Hudson Bay Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63.1K Buy
+16,820
New +$56.8K ﹤0.01% 1224
2025
Q2 		– Sell
-12,200
Closed -$18.7K – 1341
2025
Q1 		$18.7K Buy
+12,200
New +$26K ﹤0.01% 1228

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Hudson Bay Capital Management's ACRS Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 16,820 shares worth $63.1K. The stake represents ﹤0.01% of the portfolio and ranks #1224 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in ACRS as recently as Q1 2025.

Hudson Bay Capital Management first reported a position in ACRS in Q1 2025 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Hudson Bay Capital Management held 16,820 shares of Aclaris Therapeutics worth $63.1K as of Q1 2026.
  • Aclaris Therapeutics was a new Hudson Bay Capital Management position in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1224 holding.
  • Hudson Bay Capital Management first reported a position in Aclaris Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.